Tag archive for ‘Andromeda Biotech’
Gil Tanenbaum On Monday, October 27th, 2014

Clal Biotech Sells Pidilizumab Cancer Treatment Rights to Medivation

Israel’s Clal Biotechnology Industries has sold the exclusive worldwide commercialization rights for its cancer treatment pidilizumab to the American company Medivation. The rights are held by Clal subsidiary More...

Globes On Tuesday, October 7th, 2014

Clal Biotech, Hyperion seek settlement over Andromeda

– Clal Biotechnology and Hyperion have agreed on an independent assessment of Andromeda’s Type 1 diabetes treatment. –   Clal Biotechnology (TASE: CBI), managed by Reuven Krupik, and More...

Jewish Business News On Monday, September 22nd, 2014

Clal Biotech: No Evidence of Misconduct by Us

Clal Biotechnology Industries Ltd. (TASE: CBI) notified the Tel Aviv Stock Exchange this morning that it had contacted Hyperion Therapeutics Inc. (Nasdaq: HPTX) as part of its efforts to gather as much information More...

Globes On Tuesday, September 9th, 2014

Hyperion Cancels Israeli Biotech Acquisition over Falsified Clinical Trial Results

By Gali Weinreb and Shiri Habib-Valdhorn Hyperion says it has “uncovered evidence” that Andromeda falsified clinical trial results. Hyperion Therapeutics Inc. (Nasdaq: HPTX) has cancelled its acquisition More...

Wordpress site Developed by Fixing WordPress Problems